Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 8/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777018 | 0.90 | GRM5 (0.41) | MALT1GRM5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17769884 | 0.90 | GRM5 (0.41) | MALT1GRM5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17770383 | 0.88 | OPRK1 (0.37) | MALT1 | |
| SCHEMBL17776994 | 0.88 | OPRK1 (0.37) | MALT1 | |
| SCHEMBL17778560 | 0.86 | GRM5 (0.43) | GRM5NPC1RAB9AMEN1KMT2A | |
| SCHEMBL17769380 | 0.85 | GRM5 (0.44) | GRM5NPC1RAB9AMEN1KMT2A | |
| SCHEMBL19714137 | 0.84 | TRPV1 (0.37) | MALT1GRM5SMN1; SMN2RAB9ABTK | |
| SCHEMBL19714221 | 0.84 | TRPV1 (0.37) | MALT1GRM5SMN1; SMN2RAB9ABTK | |
| SCHEMBL17769452 | 0.84 | MEN1 (0.39) | GRM5RXFP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17777041 | 0.84 | MEN1 (0.39) | GRM5SMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MALT1 4351/4885GRM5 3991/4885RXFP1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.